Stemline Therapeutics (STML) Tops Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Stemline Therapeutics (STML) Tops Q1 EPS by 8c

Roth Affirms Stemline Therapeutics (STML) at 'Buy'; Focus Now on June ASCO Presentation

May 9, 2016 11:43 AM EDT

Roth Capital affirms Stemline Therapeutics (Nasdaq: STML) with a Buy rating and $32 price target after the company reported Q1 results on Monday. Stemline posted Q1 EPS of ($0.51), which was $0.08 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $205.65 million, versus $121.43 million reported last year.

Analyst Joseph Pantginis commented, Following a mostly quiet time in 2015 regarding news flow, which we... More